Barclays raised the firm’s price target on AbbVie to $195 from $185 and keeps an Overweight rating on the shares. The analyst cites a favorable key opinion leader feedback heading into the ‘951 PDUFA and believes that the drug has the potential to achieve $2.0-$2.5B in sales given the unmet need and strong market fit.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- Fly Insider: NextNav, Akamai among week’s notable insider trades
- AbbVie to acquire Landos Biopharma for $20.42 per share in cash plus CVR
- AbbVie to Acquire Landos Biopharma, Further Strengthening its Portfolio in Inflammatory and Autoimmune Diseases
- AbbVie to acquire Landos Biopharma got $20.42 per share in cash
- AbbVie to acquire Landos Biopharma for $20.42 per share in cash